Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022)
Matinas BioPharma Holdings (MTNB) posted quarterly Current Deferred Revenue of $721000.0 for Q4 2022, up 2308.39% quarter-over-quarter from $29937.0 in Q4 2017.
Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2015 - 2022) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Current Deferred Revenue for 4 consecutive years, with $721000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Current Deferred Revenue changed N/A year-over-year to $721000.0; the TTM figure through Dec 2022 stood at $721000.0 (changed N/A YoY), while the FY2022 annual figure was $721000.0, changed N/A from the prior year.
- Current Deferred Revenue advanced to $721000.0 in Q4 2022 per MTNB's latest filing, from $29937.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $721000.0 in Q4 2022 and bottomed at $721000.0 in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 721,000.00 |
| Dec 31, 2017 | 29,937.00 |
| Sep 30, 2017 | 74,844.00 |
| Jun 30, 2017 | 119,750.00 |
| Mar 31, 2017 | 11,744.00 |
| Dec 31, 2016 | 11,485.00 |
| Sep 30, 2016 | 11,226.00 |
| Jun 30, 2016 | 10,967.00 |
| Mar 31, 2016 | 10,218.00 |
| Dec 31, 2015 | 9,225.00 |
| Sep 30, 2015 | 8,232.00 |
| Jun 30, 2015 | 7,239.00 |
| Mar 31, 2015 | 5,757.00 |